Alirocumab and Cardiovascular Outcomes after Acute Coronary SyndromeGregory G. Schwartz, Andreas M. Zeiher, Philippe Gabríel Steg et al.|New England Journal of Medicine|2018Cited by 3.5k
Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or BothMarc A. Pfeffer, Robert M. Califf, John J.V. McMurray et al.|New England Journal of Medicine|2003Cited by 2.5k
Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial InfarctionNagesh S. Anavekar, Marc A. Pfeffer, Steven L. Zelenkofske et al.|New England Journal of Medicine|2004Cited by 1.9k
Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic EventsDeepak L. Bhatt, Robert A. Harrington, Gregg W. Stone et al.|New England Journal of Medicine|2013Cited by 825
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary SyndromesPierluigi Tricoci, Kenneth W. Mahaffey, Zhen Huang et al.|New England Journal of Medicine|2011Cited by 753